Our Services
Medical Information
Helpful Resources
Published on: 2/10/2026
Farxiga (dapagliflozin) in women aged 65 and older can improve blood sugar control, modestly reduce weight and blood pressure, protect heart health, and slow kidney decline. However, common side effects include genital yeast infections, urinary tract infections, and increased urination and thirst. Less common but serious risks include dehydration with low blood pressure, temporary kidney changes, and rare diabetic ketoacidosis.
Safety depends on kidney function, hydration status, other medications, and regular monitoring. Older women should know who must avoid Farxiga, when to pause it during illness, urgent warning signs to watch for, and practical tips to stay safe.
Because side effects like urinary symptoms, fatigue, or dehydration can mimic other conditions, it's worth clarifying what's really going on before your next doctor visit. Take a free, instant, online symptom check to better understand your symptoms and confidently navigate your next steps.
Reviewed for medical accuracy: 07/09/2026
Not seeing your question? No worries.
Submit your own QuestionFarxiga (dapagliflozin) is a prescription medication used to help manage type 2 diabetes, heart failure, and chronic kidney disease. For women aged 65 and older, Farxiga can offer meaningful benefits—but it also comes with specific safety considerations. This guide explains how Farxiga works, its potential benefits, common and serious side effects, and what older women should know before starting or continuing treatment.
This information is based on guidance from widely recognized medical authorities such as the U.S. Food and Drug Administration (FDA), major diabetes and cardiology organizations, and peer‑reviewed clinical studies. It is written in plain language to help you make informed decisions—without unnecessary alarm.
Farxiga belongs to a class of medications called SGLT2 inhibitors. These drugs help the kidneys remove excess glucose (sugar) from the blood through urine.
Farxiga is approved to:
Because Farxiga works through the kidneys, age-related changes in kidney function are especially important for women over 65.
For many older women, Farxiga offers benefits that go beyond blood sugar control.
These benefits can be especially meaningful for women over 65, who are more likely to have diabetes along with heart or kidney disease.
Most people tolerate Farxiga well, but side effects can happen. In women over 65, some effects are more common due to changes in immunity, hydration, and kidney function.
These side effects are usually treatable and not life-threatening, but they should be reported to a healthcare provider.
While uncommon, there are some serious risks that women 65+ should understand clearly.
Farxiga causes the body to lose fluid through urine. In older adults, this can lead to:
This risk is higher if you:
Farxiga is often used to protect kidney function long-term, but:
In rare cases, Farxiga can cause diabetic ketoacidosis (DKA), even when blood sugar is not very high.
Warning signs include:
This is a medical emergency and requires immediate care.
A very rare but serious infection of the genital area has been reported. While extremely uncommon, it is life-threatening if not treated promptly.
For many women 65 and older, Farxiga can be safe and effective when properly monitored. Safety depends on individual factors such as:
Never stop Farxiga suddenly without medical advice.
Farxiga may not be appropriate if you:
A healthcare professional can help weigh risks versus benefits.
Managing diabetes after age 65 is about more than numbers. The goals are to:
Farxiga is often chosen because it supports these broader goals, especially when combined with lifestyle measures like balanced nutrition, regular movement, and proper hydration.
If you're concerned about your symptoms or want to understand your health better, you can check whether your symptoms align with Diabetes Mellitus using a free AI-powered symptom assessment tool—though this should always be followed by a conversation with your healthcare provider for proper diagnosis and care.
Contact a healthcare professional right away if you experience:
Anything that feels life-threatening or serious should be evaluated urgently.
For women aged 65 and older, Farxiga can be a valuable medication with benefits that extend beyond blood sugar control—especially for heart and kidney health. However, age-related risks such as dehydration, infections, and kidney changes mean careful monitoring is essential.
Farxiga is not a one-size-fits-all solution. The right decision depends on your full medical picture, your daily routine, and your personal health goals. Always speak to a doctor or qualified healthcare professional before starting, stopping, or changing Farxiga—especially if you notice new or worsening symptoms.
With the right guidance and regular follow-up, many older women use Farxiga safely and successfully as part of a comprehensive care plan.
(References)
* Mochizuki, T., Ogasawara, T., Aiba, Y., & Oishi, S. (2022). Dapagliflozin safety in older adults: A systematic review and meta-analysis. *Geriatrics & Gerontology International*, *22*(3), 205-214.
* Palmer, S. C., Wahid, S., & Buse, J. B. (2020). Cardiovascular and renal benefits of SGLT2 inhibitors in older adults with type 2 diabetes: a systematic review and meta-analysis. *Journal of Geriatric Cardiology: JGC*, *17*(7), 405.
* Hanefeld, M., & Frias, J. P. (2018). Efficacy and Safety of Dapagliflozin in Older Adults with Type 2 Diabetes Mellitus: A Review. *Advances in Therapy*, *35*, 1290-1301.
* Jaiswal, V., Singh, K. D., Jain, R., Goyal, P., Ahmad, S., Dhall, N., & Puri, A. (2023). Dapagliflozin in heart failure with preserved ejection fraction in older adults: a subgroup analysis of DELIVER. *European Heart Journal: Heart Failure*, *24*(5), 902-909.
* Wheeler, D. C., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Heerspink, H. J., ... & DAPA-CKD Trial Committees and Investigators. (2021). Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease: An Analysis From the DAPA-CKD Trial. *Kidney International Reports*, *6*(5), 1018-1029.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.